Cargando…
Anti-c-myc RNAi-Based Onconanotherapeutics
Overexpression of the c-myc proto-oncogene features prominently in most human cancers. Early studies established that inhibiting the expression of oncogenic c-myc, produced potent anti-cancer effects. This gave rise to the notion that an appropriate c-myc silencing agent might provide a broadly appl...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765184/ https://www.ncbi.nlm.nih.gov/pubmed/33333729 http://dx.doi.org/10.3390/biomedicines8120612 |
_version_ | 1783628432193617920 |
---|---|
author | Habib, Saffiya Ariatti, Mario Singh, Moganavelli |
author_facet | Habib, Saffiya Ariatti, Mario Singh, Moganavelli |
author_sort | Habib, Saffiya |
collection | PubMed |
description | Overexpression of the c-myc proto-oncogene features prominently in most human cancers. Early studies established that inhibiting the expression of oncogenic c-myc, produced potent anti-cancer effects. This gave rise to the notion that an appropriate c-myc silencing agent might provide a broadly applicable and more effective form of cancer treatment than is currently available. The endogenous mechanism of RNA interference (RNAi), through which small RNA molecules induce gene silencing by binding to complementary mRNA transcripts, represents an attractive avenue for c-myc inhibition. However, the development of a clinically viable, anti-c-myc RNAi-based platform is largely dependent upon the design of an appropriate carrier of the effector nucleic acids. To date, organic and inorganic nanoparticles were assessed both in vitro and in vivo, as carriers of small interfering RNA (siRNA), DICER-substrate siRNA (DsiRNA), and short hairpin RNA (shRNA) expression plasmids, directed against the c-myc oncogene. We review here the various anti-c-myc RNAi-based nanosystems that have come to the fore, especially between 2005 and 2020. |
format | Online Article Text |
id | pubmed-7765184 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77651842020-12-27 Anti-c-myc RNAi-Based Onconanotherapeutics Habib, Saffiya Ariatti, Mario Singh, Moganavelli Biomedicines Review Overexpression of the c-myc proto-oncogene features prominently in most human cancers. Early studies established that inhibiting the expression of oncogenic c-myc, produced potent anti-cancer effects. This gave rise to the notion that an appropriate c-myc silencing agent might provide a broadly applicable and more effective form of cancer treatment than is currently available. The endogenous mechanism of RNA interference (RNAi), through which small RNA molecules induce gene silencing by binding to complementary mRNA transcripts, represents an attractive avenue for c-myc inhibition. However, the development of a clinically viable, anti-c-myc RNAi-based platform is largely dependent upon the design of an appropriate carrier of the effector nucleic acids. To date, organic and inorganic nanoparticles were assessed both in vitro and in vivo, as carriers of small interfering RNA (siRNA), DICER-substrate siRNA (DsiRNA), and short hairpin RNA (shRNA) expression plasmids, directed against the c-myc oncogene. We review here the various anti-c-myc RNAi-based nanosystems that have come to the fore, especially between 2005 and 2020. MDPI 2020-12-15 /pmc/articles/PMC7765184/ /pubmed/33333729 http://dx.doi.org/10.3390/biomedicines8120612 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Habib, Saffiya Ariatti, Mario Singh, Moganavelli Anti-c-myc RNAi-Based Onconanotherapeutics |
title | Anti-c-myc RNAi-Based Onconanotherapeutics |
title_full | Anti-c-myc RNAi-Based Onconanotherapeutics |
title_fullStr | Anti-c-myc RNAi-Based Onconanotherapeutics |
title_full_unstemmed | Anti-c-myc RNAi-Based Onconanotherapeutics |
title_short | Anti-c-myc RNAi-Based Onconanotherapeutics |
title_sort | anti-c-myc rnai-based onconanotherapeutics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765184/ https://www.ncbi.nlm.nih.gov/pubmed/33333729 http://dx.doi.org/10.3390/biomedicines8120612 |
work_keys_str_mv | AT habibsaffiya anticmycrnaibasedonconanotherapeutics AT ariattimario anticmycrnaibasedonconanotherapeutics AT singhmoganavelli anticmycrnaibasedonconanotherapeutics |